BioCentury
ARTICLE | Company News

Amygdala acquires addiction candidate from Gilead

February 16, 2017 9:05 PM UTC

Amygdala Neurosciences Inc. (Palo Alto, Calif.) said it acquired GS-6637 from Gilead Sciences Inc. (NASDAQ:GILD). The company expects to begin clinical trials this year of the candidate to treat cocaine and alcohol use disorders. GS-6637 is an aldehyde dehydrogenase 2 family mitochondrial (ALDH2) inhibitor.

Gilead developed GS-6637 based on early work by CV Therapeutics Inc., which Gilead acquired in 2009. Amygdala's management team includes several veterans of CVT...